Manual of Policies and Procedures MaPPs

Manual code system, in searching patent literature, 18 223-225 Manual of Classification, 18 209 Manuals of Policies and Procedures (MAPPs), 13 688 Manufactured carbon, 4 735 Manufactured fibers, 11 165, 174-175 24 613-614, 616-618. See also Regenerated fibers Synthetic fibers olefin, 11 231-242 regenerated cellulose, 11 247 Manufactured graphite, 4 735 Manufactured products, nanotechnology and, 17 44-45 Manufactured water, 26 96 Manufacturing... 

Manual of Policies and Procedures (MAPP 6020.3) Review Management Priority Review Policy. 

Manual of Policy and Procedures (MAPP 400.4) Clinical Pharmacology and Biopharmaceutics Review Template, http //www.fda.gov/cder/mapp/4000. 4.pdf, April 2004 (last accessed December 29, 2004). 

Internal Agency policies and procedures relating to processing requests for expedited review of supplements to approved AND As and NDAs are documented in CDER s Manual of Policies and Procedures (MAPP) at 5240.1 and 5310.3, respectively. MAPPs can be located on the Internet at http //www.fda.gov/cder/mapp.htm. 

Center for Drug Evaluation and Research (CDER). Manual of Policies and Procedures, MAPP 4512.1. Formal Meetings Between CDER and CDER s External Constituents, March 7,1996. 

FDA policies and procedures for formal meetings with external constituents described in CDER s Manual of Policy and Procedures (MAPP 4512.1) and CBER Standard Operating Procedures and Policies (SOPP) 8101.1... 

Manual of Policies and Procedures (MaPPs). CDER s MaPPs are approved instructions for internal practices and procedures followed by CDER staff to help standardize the new drug review process and other activities. MaPPs define external activities as well. All MAPPs are available for the public to review to get a better understanding of office policies, definitions, staff responsibilities, and procedures. MaPPs of particular interest to IND sponsors include the following ... 

Manual of Policies and Procedures (MaPP6010.2). Review management. Procedures for tracking and reviewing phase 4 commitments, URL http //www.fda.-gov/cder/mapp/6010-2.pdf, accessed 3-10-2001. 

Traditional bases for regulatory considerations are the code of federal regulations (CFR), the domestic guidances issued by drug regulatory agencies, the International Conference on Harmonization of Technical Requirements for Restoration of Pharmaceuticals for Human Use (ICH) guidance, the reviewer MAPP (manual of policies and procedures), current scientific standards, and precedents. 

---